CD274 and neoplasm: Conversely, in our series, six patients (17%) received nivolumab in the first-line setting, irrespective of PD-L1 tumor expression, and thus outside of the guidelines and Food and Drug Administration (FDA)/European Medicines Agency (EMA)-approved indications, and prior to the CheckMate 026 negative trial being published [18].